

Sasha Mazzearello

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7803014/sasha-mazzearello-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

725
citations

16
h-index

23
g-index

60
ext. papers

861
ext. citations

4
avg, IF

3.82
L-index

#	Paper	IF	Citations
60	A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers. <i>PLoS ONE</i> , 2021 , 16, e0248238	3.7	0
59	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021 , 142, 132-140	7.5	20
58	The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 832-846	7.6	8
57	A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer. <i>Supportive Care in Cancer</i> , 2020 , 28, 4891-4899	3.9	8
56	A comparison of policy provisions for managing "financial" and "non-financial" interests across health-related research organizations: A qualitative content analysis. <i>Accountability in Research</i> , 2020 , 27, 212-237	1.9	6
55	Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. <i>Oncology Nursing Forum</i> , 2020 , 47, E86-E106	1.7	7
54	Risk Factors for Failure to Rescue in Myocardial Infarction after Noncardiac Surgery: A Cohort Study. <i>Anesthesiology</i> , 2020 , 133, 96-108	4.3	3
53	Conflict of interest as ethical shorthand: understanding the range and nature of "non-financial conflict of interest" in biomedicine. <i>Journal of Clinical Epidemiology</i> , 2020 , 120, 1-7	5.7	18
52	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 507-517	4.4	11
51	Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019 , 25, 196-204	2.5	7
50	Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). <i>Supportive Care in Cancer</i> , 2019 , 27, 1217-1224	3.9	5
49	A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 337-345	4.4	3
48	Postoperative shared-care for patients undergoing non-cardiac surgery: a systematic review and meta-analysis. <i>Canadian Journal of Anaesthesia</i> , 2019 , 66, 1095-1105	3	2
47	Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2019 , 19, e40-e47	3	7
46	A prospective intervention to improve happiness and reduce burnout in oncologists. <i>Supportive Care in Cancer</i> , 2019 , 27, 1563-1572	3.9	5
45	Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2018 , 26, 2323-2331	3.9	6
44	A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 371-379	4.4	7

43	Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	6
42	Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. <i>Stem Cells Translational Medicine</i> , 2018 , 7, 857-866	6.9	63
41	Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2017 , 25, 1881-1886	3.9	8
40	Predatory Invitations from Journals: More Than Just a Nuisance?. <i>Oncologist</i> , 2017 , 22, 236-240	5.7	28
39	A cost-utility analysis of risk model-guided versus physician choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. <i>Supportive Care in Cancer</i> , 2017 , 25, 2505-2513	3.9	4
38	Is This Conference for Real? Navigating Presumed Predatory Conference Invitations. <i>Journal of Oncology Practice</i> , 2017 , 13, 410-413	3.1	14
37	Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 1-10	4.4	18
36	A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 1-6	3.3	9
35	Comparison of two care schedules for monitoring of cardiotoxicity in patients receiving trastuzumab-based therapy for early-stage breast cancer: study protocol for a randomized controlled non-inferiority trial. <i>Clinical Trials in Degenerative Diseases</i> , 2017 , 2, 40	0.1	1
34	Risk Model-Guided Antiemetic Prophylaxis vs Physician Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 225-31	13.4	27
33	Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. <i>Supportive Care in Cancer</i> , 2016 , 24, 1563-9	3.9	14
32	Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 337-44	4.4	13
31	Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. <i>Supportive Care in Cancer</i> , 2016 , 24, 1583-94	3.9	25
30	Weight control strategies in breast cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 179-179	2.2	
29	Optimal weight control strategies in cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10109-10109	2.2	
28	A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21594-e21594	2.2	
27	A simple approach for eliminating spam. <i>Current Oncology</i> , 2016 , 23, e75-6	2.8	7
26	Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, e1016-e1024	3.1	22

25	De-escalation of bone-targeted agents for metastatic prostate cancer. <i>Current Oncology</i> , 2016 , 23, e77-82.8		6
24	Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016 , 5, 57-62	4.5	8
23	Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. <i>Supportive Care in Cancer</i> , 2016 , 24, 3633-50	3.9	23
22	Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions. <i>Journal of Bone Oncology</i> , 2016 , 5, 180-184	4.5	1
21	Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients-A Systematic Review. <i>Clinical Breast Cancer</i> , 2016 , 16, 456-470	3	17
20	Defining optimal control of chemotherapy-induced nausea and vomiting-based on patientsU experience. <i>Supportive Care in Cancer</i> , 2015 , 23, 3341-59	3.9	31
19	Surviving Surveys. <i>Journal of Oncology Practice</i> , 2015 , 11, 44-6	3.1	9
18	Nipple discharge. <i>Cmaj</i> , 2015 , 187, 599	3.5	4
17	Dosing Strategies of Bone-Targeting Agents. <i>JAMA Internal Medicine</i> , 2015 , 175, 1864-5	11.5	4
16	Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making. <i>Cancer Treatment Reviews</i> , 2015 , 41, 951-9	14.4	9
15	Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 1-8	4.4	22
14	Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. <i>Supportive Care in Cancer</i> , 2015 , 23, 3269-75	7.9	16
13	Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. <i>Systematic Reviews</i> , 2015 , 4, 114	3	13
12	Should de-escalation of bone-targeted agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17711-e17711	2.2	
11	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 615-24	4.4	22
10	Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. <i>SpringerPlus</i> , 2014 , 3, 176		24
9	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. <i>SpringerPlus</i> , 2014 , 3, 577		14
8	Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. <i>Oncologist</i> , 2014 , 19, 127-34	5.7	57

7	A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 155-155	2.2	1
6	De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists. <i>Journal of Bone Oncology</i> , 2013 , 2, 77-83	4.5	22
5	Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. <i>Journal of Bone Oncology</i> , 2013 , 2, 105-9	4.5	15
4	Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. <i>Journal of Bone Oncology</i> , 2013 , 2, 38-46	4.5	14
3	Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. <i>Journal of Clinical Medicine</i> , 2013 , 2, 67-88	5.1	7
2	Patient perceptions about potential side effects and benefits from chemotherapy agents.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6595-6595	2.2	4
1	Serum activinA and TGF- β s biomarkers of breast cancer bone metastasis behavior.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10620-10620	2.2	